| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 3.1B | +1% |
| Operating Income | 389.9MM | -21% |
| Operating Expenses | 2.8B | - |
| Net Income | 150.7MM | -39% |
| G&A | 401.5MM | +7% |
| Amortization | 195.3MM | +4% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Philips (PHG) announces the FDA clearance for its Zenition 30 mobile C-arm, which is intended to aid in image-guided procedures at a relatively affordable cost.
Recently, Zacks.com users have been paying close attention to DaVita HealthCare (DVA). This makes it worthwhile to examine what the stock has in store.
The S&P 500 rebounded Monday, led by Ford, United Airlines and megacap AI stock Nvidia. Verizon and Tesla were notable losers.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Neogen (NEOG) announces a genomics relationship with Performance Food Group to trace food products back to their origin using PathProven food trace technology.
By 2025, DaVita (NYSE: DVA), a leading provider of kidney care services, expects to match 100% of its electricity use across its global operations with renewable energy purchases. DaVita has contracted with ACCIONA Energía on a virtual power purchase agreement (PPA) facilitating the development of clean energy projects in Spain. This announcement follows DaVita reaching 100% renewable in its North American operations in December 2021.
DaVita HealthCare (DVA) closed at $127.82 in the latest trading session, marking a +1.36% move from the prior day.
Masimo's (MASI) R&D activities raise optimism about the stock.
CVRx's (CVRX) announcement of the availability of additional data supporting the long-term benefits of Barostim is likely to lead to improved patient care.
GE HealthCare (GEHC) announces its latest AI-powered Voluson Signature 20 and 18 ultrasound systems, which are likely to provide effective and efficient care for conditions impacting women's health.